|
Re: The prognostic and predictive impact of BMI on clinical outcome of HER2-positive
Until each of us is seen by an endocrinologist at the time our treatment plan is set up in the same way that we see a surgeon or an oncologist or a radiologist, there is no recognition or acknowledgement being made that our individual metabolic management is part of the solution and our metabolic situation should be calculated as part of our risk and part of our treatment plan.
Permanent changes in metabolism and weight are less likely among the younger population because they are less likely to become fully postmenopausal with treatment, although most breast cancer patients do gain some weight with treatment.
However, the vast majority of breast cancer patients (including the vast majority of early stage breast cancer patients) are age 50 or older.
A.A.
__________________
Dx 2002 age 51
bc for granny, aunt, cousin, sister, mother.
ER+/PR+/HER2+++, grade 3
IDC 1.9 cm, some DCIS, Stage 1, Grade 3
Lumpectomy, CAFx6 (no blood boosters), IMRT rads, 1 3/4 yr tamoxifen
Rads necrosis
BRCA 1 & 2 negative
Trials: Early detection OVCA; 2004 low-dose testosterone for bc survivors
Diet: Primarily vegetarian organic; metformin (no diabetes), vitamin D3
Exercise: 7 days a week, 1 hr/day
No trastuzumab, no taxane, no AI
NED
|